• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Tatton Consulting

  • 🏆 Grants Consultancy of the Year 2020 & 2021 🏆
  • About us
  • Submit your Enquiry
  • Contact Us
  • How We Help
  • Our Team
  • Our Successes
  • Funding Opportunities
  • Eligibility
    • Innovate UK opportunities
    • COVID-19 grants
    • Defence & Security grants
    • Industrial Strategy Challenge Fund
    • Regional Investment grants
    • EU funding opportunities
  • Pricing

Mark Clayton

Two of Tatton’s Medtech clients featured in an industry ‘ones to watch’ list.

December 8, 2020 By Mark Clayton

Big AI projects in medicine to watch in 2020

  • Download PDF Copy

Significant, transformational grants won for both this year – 2021 should see them rocket in growth 🚀 #grants #innovateuk #disrupt #tattonconsulting #startups #innovation #venturecapital

Artificial intelligence (AI) is beginning to touch medicine in many different ways, from making diagnoses to triaging patients. Many AI enterprises will make headlines in 2020:

GlobalData’s medical devices writer Chloe Kent singles out three big projects to watch this year.

Abtrace battles against antimicrobial resistance

Kent says:

Antimicrobial resistance (AMR) is one of the greatest ongoing threats to global health, estimated to cause 25,000 deaths and 2.5 million extra hospital stays per year in Europe alone.

Leading the fight against antimicrobial resistance in the tech world is Abtrace, an AI platform designed to help clinicians prescribe the most appropriate antibiotic for each individual patient they see in their practice. When around 30% of antibiotic prescriptions are inappropriate, this couldn’t come at a more vital time.

The platform makes its recommendations through a process known as natural language processing (NLP), where a patient’s healthcare notes are processed through Abtrace’s augmented decision-making tool. In seconds, it presents a recommendation for whether or not an antibiotic should be prescribed, and which antibiotic would be appropriate if so.

Abtrace is a European Institute of Technology Health (EIT Health) Wild Card Project, and will receive up to €2m from the organization to help commercialize the product.”

Pexxi genetic testing aims to decode contraception

Kent says:

Many women who choose to use hormonal contraceptives, such as the pill, implant or ring, have to navigate several different options through trial-and-error until they are able to find a medication that works for them.

The side effects associated with hormonal contraceptives, such as acne, weight gain, anxiety and depression, can have a huge effect on a person’s life, and it can take months or even years before a woman is able to settle on one with no or only minimal adverse effects.

Healthtech start-up Pexxi is aiming to end the contraceptive roulette wheel through AI-powered genetic testing. Users give Pexxi a spit sample, which contains enough information about where their progesterone and estrogen levels naturally sit, as well as whether they have any genetic predispositions to the potential side-effects of one type of pill over another. Pexxi then provides a list of the contraceptive pills the person is most likely to tolerate, with plans to eventually expand to include the implant and ring as well. Pexxi is currently in beta-testing stages, with a plan to eventually reach customers through a 23andMe-style model where they’ll pay a fee to use its services.”

Source:

GlobalData

Filed Under: Uncategorized Tagged With: digital health, funding, grants, innovateUK, innovation, medtech

Tatton appointed the official Grants Partner of KQ Labs @ The Francis Crick Institute

November 11, 2020 By Mark Clayton

Run once a year by the Crick and supported by LifeArc, ten start-ups with the potential to make an impact on global health outcomes have access to unrivalled support and resources.

KQ Labs helps early-stage data-driven health startup founders to validate their ideas and put their startups on a path to receive investment from business angel investors, venture capital and other sources including non-dilutive funding in the form of grants.

The accelerator is called KQ Labs to represent the ‘Knowledge Quarter’ area around the King’s Cross, Euston and Bloomsbury regions of the city. The KQ Labs accelerator represents a unique opportunity to foster a vibrant ecosystem for data-driven health.

The 16-week programme includes funding (£40k) in the form of a convertible loan, weekly workshops with experts tailored to digital health, training in transferable skills, mentoring by a hand-picked network of experts, and discussions with investors and corporates. In addition, the KQ Labs network facilitates access to data (eg from Health Data Research UK or Genomics England) for start-ups that need to validate their technology further. The programme culminates in a Demo Day, when the startups pitch their propositions to potential investors and partners. All selected startup teams have access to a powerful network of global experts in entrepreneurship, health sector expertise, data science and investment strategies.                                                                           

KQ Labs logo

The KQ Labs accelerator programme

  • Specialised investor introductions
  • Introductions to major corporates, especially pharma
  • Mentoring opportunities with a hand-picked network of experts
  • Tailored and customised weekly workshops covering:
    • Data accessibility and ethics
    • Finance and fundraising
    • Customer and market focus
    • Leadership and team building
    • Communications and pitching practice
    • Regulatory requirements
    • Protecting Intellectual Property
    • Corporate legal aspects
    • Market access (UK and international)
    • Scaling
    • Grant funding and writing

Alumni

Find out more about the previous cohorts of KQ Labs start-ups on our alumni page.

Filed Under: Uncategorized Tagged With: digital health, grants, innovateUK, innovation, KQ Labs, SMART

Six Innovate UK grants secured by Tatton for sustainable packaging developer Notpla

October 27, 2020 By Mark Clayton

Filed Under: Uncategorized Tagged With: grants, grants funding innovation innovateUK, SMART

£350k grant for Byotrol and Liverpool University to explore the anti-viral properties of seaweed

September 8, 2020 By Mark Clayton

Researchers at Byotrol plc and the University of Liverpool are set to investigate the anti-viral properties of seaweed.

The new project is a collaboration with industrial partner Byotrol plc and will focus on the potential use of anti-viral seaweed compounds in sanitising products, such as hand gels and household cleaners.

The team has been awarded £350K of funding by Innovate UK to carry out the work over the next 16 months.

Easily spread and immune to antibiotics, viruses are very difficult to eradicate and even more expensive to treat, with a limited number of anti-viral solutions. Despite rapid advances in medical and cleaning technology, viruses such as norovirus, influenza and coronavirus continue to pose a major threat to human health and cost the UK billions each year.

AIM-listed hygiene group Byotrol has, for some time, been investigating sustainably sourced anti-virals and has found certain forms of seaweed to have particularly good potential.

The University’s Molecular Virology Research Group will use their expertise to characterise the anti-viral component of the seaweed, evaluate the efficacy of a much broader range of seaweed species and determine its anti-viral mode of action.

Professor James Stewart, who is leading the project at the University of Liverpool, said: “The current COVID-19 pandemic has highlighted the need to develop new anti-viral countermeasures, especially ones that are environmentally sustainable. We are excited to be working with Byotrol on the development of these compounds.”

Dr Trevor Francis, Chief Technology Officer of Byotrol plc, said: “We are delighted that Innovate UK is supporting our research into the anti-viral properties of seaweeds and we are very pleased to be working on this project with Professor James Stewart’s excellent team at the University of Liverpool. It is a very exciting area of development for Byotrol.”/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.

Filed Under: Uncategorized Tagged With: COVID, funding, grants, innovateUK, innovation, SMART

UKRI & Innovate UK – Updated COVID priority areas

August 27, 2020 By Mark Clayton

Thinking of applying for the UKRI COVID-19 open call? As the pandemic progresses, UKRI and Innovate UK looking to fill gaps in the research and innovation landscape. Check out the list of priority areas and what’s already being funded before you begin;

Priority areas

Modelling, AI, digital and data approaches to understanding of the COVID-19 pandemic and mitigating its effects

  • Data: preparation of data sets to defined quality standards for research; trusted research environments to make data widely available and enable data linkage for research with appropriate levels of privacy, security and transparent acknowledgment of representativeness; development of highly efficient data storage and transfer systems for rapid joint analysis of large data sets.
  • Machine learning, deep learning and AI: to make actionable predictions from data and understand and mitigate against further waves of infection. Examples could include trust, data privacy and other ethical issues related to contact tracing, virus testing, workplace and wider societal monitoring, or predicting human behaviour.
  • Modelling – new models for bio-molecular simulations, epidemiology, transmission in different environments, and effectiveness of barriers to infection; model validation, reproducibility and uncertainty quantification.

Engineering and physical sciences approaches for national recovery and transformation

  • Technology development and adaptation to aid national recovery and new ways of working, including within industry and new working environments (e.g. home working).
  • Understanding the effects of the pandemic on the energy transition towards net zero and how the UK will meet its energy demand and production requirements.
  • Adaptable and reconfigurable manufacturing, to allow scale-up of COVID-19 related products quickly, efficiently and at volume.

Understanding, monitoring and controlling COVID-19 transmission

  • Understanding, monitoring and controlling COVID-19 transmission in health and social care settings and systems: projects should include information on the effectiveness of current interventions and suggest the optimum raft of interventions
  • Understanding and monitoring how viral transmission occurs: particularly indoors and within transport systems; projects should include information on the effectiveness of current interventions and suggest the optimum raft of interventions.
  • Controlling transmission through better design and manufacturing of PPE or other protective materials (including recyclable and reusable), new anti-viral surfaces or cleaning methodologies; managing air and people flows and adapting urban environments.

COVID-19 in the environment

  • What are the environmental factors (both natural and anthropogenic) which have a detectable effect on the transmission of the virus? Examples include air quality and weather. Projects should include information on the effectiveness of current interventions and suggest the optimum raft of interventions.
  • How does the virus move through and persist in the environment (biotic, abiotic and built) to help understand and detect the potential for re-emergence? Projects should include information on the effectiveness of current interventions and suggest the optimum raft of interventions.
  • Which environmental factors exacerbate or diminish the impact of the virus and the severity of the disease? Projects should include information on the effectiveness of current interventions and suggest the optimum raft of interventions.

COVID-19 Human – Animal interface

  • Research on preventing transmission between animals and humans including future spill-over events through: surveillance and characterisation of SARS-CoV-2 in animal reservoirs and identifying the potential for reverse zoonoses; understanding virus maintenance and prevalence in animal reservoirs / intermediate animal hosts; understanding modalities of transmission between animals, and from animals (including companion animals) to humans, and how the virus may survive on various surfaces, including animal fur. Projects should include information on the effectiveness of current interventions and suggest the optimum raft of interventions
  • Developing a One Health approach for future risk reduction strategies at the animal-human- environment interface including biosafety in food production systems and farms, and understanding the socio-geographic origins of zoonotic viruses.

Greening the recovery

  • How can we quantify the impacts of the epidemic induced restrictions on the environment? Providing a baseline against which the environmental effects of economic and social recovery may be measured.
  • How do we protect and build on the improvements made in the environment prior to the pandemic (e.g. pollution, greenhouse emissions) as the economy starts to grow again, and ensure future investment including in infrastructure embodies environmental ambitions?
  • What are the environmental impacts / benefits of behaviour change due to the epidemic (e.g. greenhouse gas emissions; particulates and other pollutants) including any potential changes during recovery? For example, travel to work, use of green spaces? What are these impacts/benefits at local, national and global scales, and how can benefits be retained?

Policy and behavioural change

  • What behavioural responses are most effective – singly and in combination – at reducing infection?
  • Which behavioural responses are most effective in different risk environments at work, at home, during transport, etc (work in this area should include consideration of the viral load)?

Economic impacts and micro-, macro- and fiscal economic policy

  • We continue to need more work on identifying those policies which will be effective in restarting the economy and encouraging recovery and long term renewal (including macroeconomic policies).
  • How can we limit the ‘scarring’ effects of the pandemic, and its damage to human, natural, physical and social capital (including to vulnerable groups and across the regions and nations of the UK), and how can economic analysis and policy ensure improved future outcomes?
  • What impact has the pandemic already had upon different parts of the UK, different organisations and sectors, work patterns, the make-up of the workforce, inter-sectoral flows and supply chains, and current and future demand for jobs, skills, and economic assets (such as office space and transport infrastructure)? What future impacts are anticipated, and what are the appropriate policy responses?

Social impact upon vulnerable groups and regions

  • Research on the uneven epidemiological, economic, psychological and social impacts of the pandemic across society, with a particular focus on identifying those most at risk and how policy

making can best support them. Particular gaps are noted in relation to BAME communities and children and young people.

  • Research on communities and how they help support vulnerable people, families and groups. This includes research to understand how civil society, the voluntary sector and faith groups have acted and how their actions have influenced community resilience.

Impacts of COVID-19 on cultural and creative sector

  • The ‘digital turn’ in cultural consumption: opportunities and limitations.
  • Impacts of creative/cultural sector on mental health and well-being under lockdown and during emergence from lockdown.
  • Role of cultural and creative sector in emergence from COVID/post-COVID recovery.

Ethical, Regulatory and Human Rights issues in responses to COVID-19

  • Ethics of prioritization of COVID-related healthcare decisions and interventions
  • Data and AI ethics in relation to COVID-19 public health measures e.g. tracing apps
  • Ethical dimensions of (un)equal impacts of COVID-related decision-making
  • Ethical dimensions of pandemic response and policing activities
  • Tensions between collective actions/obligations and individual and human rights

Communication and Public Health during the pandemic

  • Design and the effective communication of official health guidance
  • Identifying and creating trusted public health information sources
  • Communicating a diversity of COVID-19 experiences

Mechanistic studies of the disease and its sequela

  • Identification of key biomarkers of infection severity and immune protection; better understanding the immune response of asymptomatic disease carriers; identifying the effects of age, gender, ethnicity, health status and the influence of co-infecting respiratory pathogens on the immune response to primary infection. Projects should suggest the optimum raft of interventions.
  • Virology, Immunity and Pathophysiology: research focused on defining critical biological/pathological parameters necessary for the prioritisation of preventative, supportive and/or therapeutic interventions. This includes understanding viral genotype/phenotype relationships, the immunology and immunopathology of the disease, the immunity generated post-severe, -mild and -asymptomatic infection and the persistence of that immunity. Studies should ensure they include relevant links to epidemiology or clinical expertise and where appropriate the established large-scale studies and consortia in this area.
  • Mental Health and Neurological Consequences- Studies understanding the biological contributors of the disease, its management and/or isolation on mental health, mental illnesses, and neurological consequences, including assessment of the presence and pathology of the virus in the brain. Development of interventions to better manage mental health and neurological consequences.

Epidemiology

  • Transmission – Research that will enable better understanding of the nature of transmission of and exposure to the virus, including quantifying the infectious dose, understanding the relationship between viral RNA and the amount of infectious virus, duration of viral shedding,

transmission from asymptomatic cases and children, and understanding the role of aerosols, surfaces, buildings and their features.

  • Settings: community epidemiology in non-health or social care settings, for example homes, workplaces, schools, universities, prisons and homeless hostels.
  • Disease Susceptibility and Severity: understanding susceptibility of different populations (age, sex, ethnicity, demographics, occupation etc.), including vulnerable and marginalised groups such as the homeless and drug users. Characterization of the spectrum of clinical manifestations, both acute and longer term, and disease severity of SARS-CoV2 infections, including potential contribution of viral load, kinetics and genotype, sites of infection and associated immunopathology, variability in immune responses, collateral tissue damage, and associated factors (demographics, etc.).
  • Control and Mitigation: research to understand social distancing measures that are most effective at preventing or reducing spread of SARS-CoV2, and how such distancing, shielding and isolation measures may be most effectively relaxed.

Intervention development and early evaluation, including experimental medicine studies

  • Diagnostics: rapid point-of-care diagnostics for use at the community level in different settings and in the context of seasonal respiratory viral infection. Proposals will need to justify their added value robustly, in the context of significant existing activity, and to provide strong evidence in terms of deliverability and route to commercialisation, at scale and speed.
  • Primary, Adjunctive and Supportive Therapies: development and evaluation, including experimental medicine studies, of the effect of primary, adjunctive and supportive interventions and therapies, including immune modulators. Proposals will need to be placed in the context of work already underway in this area, including as listed in the WHO directory of clinical trials.
  • Vaccines: development and evaluation of investigational vaccines and passive immunological approaches, improved collaboration and comparison across different studies. Proposals will need to justify their case robustly for funding, against the significant existing international activity in this area.

Filed Under: Uncategorized

£1.5m grant secured for Innovate Energy Catalyst project in Uganda

August 26, 2020 By Mark Clayton

Green energy supply in Africa is set for a major boost after the UK government announced winners of an investment package for the continent’s clean energy infrastructure at the African Investment Summit today.

Solar farms in Kenya, geothermal power stations in Ethiopia and clean energy storage across sub-Saharan Africa will receive funding and see leading UK scientists and financial experts working with their African counterparts to realise the continent’s huge potential for renewable energy.

With African energy demand set to rise by 60% by 2040, UK experts will help deliver green solutions for the continent’s growing energy needs, bringing clean energy to thousands of people and creating jobs and increased prosperity.

Business and Energy Secretary Andrea Leadsom said:

Our world-leading scientists and financial experts will work hand in hand with African nations to support their quest for energy security, powering new industries and jobs across the continent with a diverse mix of energy sources while promoting economic growth.

Speaking at the summit, Ms Leadsom emphasised the opportunity for many African countries to leapfrog coal power to cleaner forms of energy but stressed that more needed to be done to unlock investment.

A world-leader in reducing carbon emissions at home, today’s investment in global clean energy comes after the Prime Minister, Boris Johnson, announced the £1 billion ‘Ayrton Fund’ for British scientists last Autumn to help developing nations reduce reliance on fossil fuels and reduce their carbon emissions.

As part of the initiatives announced today, the UK will support African countries with the technical skills and expertise they need in order to attract investment in renewable projects, getting innovative projects like wind and solar farms up and running. Close collaboration with African countries will be key as the UK gears up to host the UN climate talks (COP26) later this year.

UK funded projects in Africa include winners of the Energy Catalyst Competition, which has seen solar plants, energy storage batteries and hydro-power built in countries such as Botswana and Kenya; a £10 million programme which matches UK based green finance experts with project developers from developing countries to facilitate investment in clean energy projects; and the Nigeria 2050 calculator, a modelling tool designed by UK scientists to support the Nigerian government’s sustainable development planning.

Kenya is also set to benefit from a £30 million government investment in affordable energy-efficient housing which will see the construction of 10,000 low-carbon homes for rent and sale. This will support the creation of new jobs in Kenya’s green construction industry and help tackle climate change.

Over 50% of the UK’s energy production came from renewable sources last year, and with London’s expertise as the global hub for green finance, the UK is best placed to be Africa’s leading partner and help it harness its wealth of renewable sources as it moves away from coal power.

Filed Under: Uncategorized

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

Contact Us

Footer

Get in touch

Get in touch now and one of our experts will contact you to discuss your project further;

Submit an enquiry
Email: funding@tattonconsulting.co.uk
Tweet: @UKgrantfunding

Company Number: 09073093
VAT Number: GB 213 0344 66

 

  • Email
  • LinkedIn
  • Twitter

Come meet us

Tatton Consulting Ltd
The Innovation Centre,
Sci-Tech Daresbury,
Keckwick Lane,
Daresbury
WA4 4FS

Find us


UK Grant Funding Partners

Copyright © 2021 · Tatton Consulting · site by Maloney IT